The tweet was deleted by the author.
But we saved everything 🙂.
BioAge Labs, Inc. draws attention to inflammation as a common element driving diseases across diverse medical fields. The statement echoes insight from Harvard cardiologist Peter Libby, featured in a recent New York Times article, who argues that disciplines such as cardiology, oncology, neurology, and rheumatology are now converging around inflammation’s central role.
This shift is reframing approaches to research and treatment, suggesting that targeting inflammatory processes may hold promise for breakthrough therapies in multiple major diseases. The recognition of this shared underlying process is prompting interdisciplinary collaboration and could accelerate medical innovation.
View post on X Loading...
BioAge Labs, Inc. recently began a Phase 2 clinical trial for a drug targeting obesity and cardiovascular risk. The company is also planning a proof-of-concept eye study. These initiatives highlight BioAge's ongoing efforts in treatments that intersect with inflammation’s role in disease.